Cases & Deals

  • Home
  • Practices
  • Celgene acquires Triphase Accelerator's first compound, Marizomib

Share

Celgene acquires Triphase Accelerator's first compound, Marizomib

November 2016

Client(s) Celgene Corporation

Jones Day advised Celgene Corporation in the acquisition, through an affiliate, of Triphase Accelerator Corporation's assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.

In addition to M&A representation, Jones Day provided health care, intellectual property, tax, and regulatory advice regarding this transaction.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.